The Danish pharmaceutical giant behind Ozempic and Wegovy said an experimental weight-loss shot helped patients lose 22% of their body weight in a clinical trial. Based on Friday’s results, Novo said it is now planning further clinical development of amycretin in overweight or obese adults. The new study comes a month after Novo shares suffered a big blow when the company reported disappointing results of a different experimental weight-loss drug, CagriSema.